display
Berlin (dpa) - The Berlin University Clinic Charité and the also state-owned clinic operator Vivantes have stopped all vaccinations of their employees under the age of 55 with the Astrazeneca preparation until further notice.
"This step is necessary from the point of view of the Charité, since further cerebral vein thromboses in women in Germany have become known in the meantime," said the spokeswoman for the Charité, Manuela Zingl, on Tuesday.
Vivantes suspended the vaccinations for women under 55 as a precaution from Tuesday.
This mainly affects the own workforce, said a spokeswoman.
Further details should be given in the afternoon.
display
In North Rhine-Westphalia, the heads of five of the six university clinics spoke out in favor of a temporary stop to vaccinations of younger women with the active ingredient from Astrazeneca.
The risk of further deaths is too high, according to a joint letter to the federal and state health ministers, which is available to the German press agency.
Charité spokeswoman Zingl emphasized that there were no complications at the Charité after vaccinations with Astrazeneca.
However, this wants to act as a precaution and wait for final evaluations.
During the pandemic, the Charité has given around 16,000 first and second vaccinations to its staff.
"Astrazeneca accounted for the largest part of this," said Zingl.
Germany - and numerous other countries - had temporarily suspended vaccination with the Astrazeneca substance in March because several cases of thrombosis (blood clots) in the cerebral veins were reported in relation to the vaccination.
The vaccine is now being given again.
The European Medicines Agency Ema had confirmed the safety of the vaccine, and the Standing Vaccination Commission in Germany had spoken out in favor of further use of the product.
display
The district of Euskirchen in North Rhine-Westphalia had already temporarily stopped the corona vaccination of women under 55 with the active ingredient from Astrazeneca on Monday.
After a vaccinated woman (47) died last week, the district was now reported to have suspected “a serious illness” in a 28-year-old after being vaccinated with Astrazeneca, it said.
Both had suffered a sinus vein thrombosis, according to the district.
In Germany, 31 cases of sinus vein thrombosis after vaccination with the Astrazeneca vaccine are known, as the Paul Ehrlich Institute reported on Tuesday.
By noon on Monday (March 29), 31 cases had been reported to the institute, and thrombocytopenia was also reported in 19 cases.
In nine cases, the outcome was fatal, as the institute responsible for vaccine safety in Langen reported.
With the exception of two cases, according to the PEI, all reports concerned women aged 20 to 63 years.
The two men were 36 and 57 years old.
According to the Robert Koch Institute's vaccination rate monitoring, 2.7 million first doses and 767 second doses of Astrazeneca had been vaccinated up to and including Monday.
© dpa-infocom, dpa: 210330-99-26747 / 3